文献速递消化道肿瘤放疗放疗物理与技术

局部晚期直肠癌新辅助放化疗联合或不联合放疗剂量强化:多中心回顾性研究ATLANTIS第一部分

Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study - ATLANTIS part I.
PubMed 文献 · Radiother Oncol · 2024-12-25

该多中心回顾性研究分析了1028例局部晚期直肠癌患者,比较新辅助放化疗联合(364例)或不联合(664例)放疗boost的pCR率。Boost组pCR为26.6%,无boost组为17%(p=0.00),boost组≥3级急性胃肠道毒性更高(6% vs 1.7%,p=0.003)。延长手术间隔在无boost组pCR仅部分改善,而boost组随时间推移pCR进行性显著改善。

要点

  • Boost组pCR 26.6% vs 无boost组17%(p=0.00)。
  • Boost组≥3级急性胃肠道毒性6% vs 无boost组1.7%(p=0.003)。
  • cT3且手术≥11周及cT4患者(无论手术时间)从boost显著获益。

核心结论

  • 局部晚期直肠癌放疗剂量强化(boost)可能显著提高pCR率,但急性毒性有小幅增加。
  • 无boost组延长手术间隔pCR仅部分改善,而boost组随时间推移pCR进行性显著改善。
  • 放疗boost似乎仅对更晚期的原发肿瘤有益。

研究设计与样本

  • 多中心回顾性研究,收集12个中心数据。
  • 共分析1028例局部晚期直肠癌患者,所有患者接受联合放化疗,其中boost组364例、无boost组664例。
  • 主要终点为放疗剂量强化是否与pCR增加相关;次要终点包括放疗剂量与手术间隔、降期及放疗相关毒性的关系;并按原发肿瘤分期进行亚组分析。

主要发现

  • 总体pCR率为21.5%。
  • Boost组pCR为26.6%(97例),无boost组为17%(114例)(p=0.00)。
  • 按手术间隔分层,boost组pCR分别为10%、23%、26.3%、39.3%(p<0.000),无boost组分别为10.6%、20.8%、19.3%、20.4%(p=0.018)。
  • cT3且手术≥11周的患者及cT4患者(无论手术时间)从boost获得显著的pCR率获益。
  • Boost组≥3级急性胃肠道毒性发生率高于无boost组(6% vs 1.7%;p=0.003)。

临床怎么用

  • 对于局部晚期直肠癌,新辅助放化疗联合放疗boost可能提高pCR率,但需注意≥3级急性胃肠道毒性增加。
  • cT3且手术间隔≥11周及cT4患者可能从放疗boost中显著获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Preoperative radiochemotherapy (RCHT) is the standard of care for locally advanced rectal cancer (LARC). While there are several data regarding chemotherapy intensification, actually, no reliable data directly comparing different radiotherapy (RT) dose levels are available. The present study aimed to compare intensified RT versus standard dose in patients with LARC. MATERIALS AND METHODS: Data from 12 centers were collected for the current large retrospective study. The primary end-point evaluated whether RT dose intensification was associated with an increased pathological complete response (pCR). The secondary end-points explored the relation between RT dose and interval to surgery, downstaging, and RT-related toxicity. Subgroup analysis according to primary tumor stage was also performed. RESULTS: 1028 patients were analysed. All patients received combined RCHT with (364) or without (664) a RT boost. Patients underwent surgery after a median 10 weeks (IQ range 5-28). The overall pCR rate was 21.5 %. In the boost and no-boost groups, the pCR was 26.6 % (97) and 17 % (114) (p = 0.00), respectively. As a subgroup analysis, the pCR stratified by interval to surgery was 10 %, 23 %, 26.3 %, and 39.3 % (p < 0.000) in the boost group versus 10.6 %, 20.8 %, 19.3 %, and 20.4 % (p = 0.018) in the no-boost group. cT3 patients operated on ≥ week 11 and cT4 patients, regardless of time to surgery, received a significant benefit by the RT boost in terms of pCR rate. Patients in the boost group had a higher rate of grade ≥ 3 acute gastrointestinal toxicities (6 % vs. 1.7 %; p = 0.003). CONCLUSION: Our results suggest that RT dose intensification (boost) in LARC might significantly increase the pCR rate, although with a small increase in acute toxicity. While pCR seems only partially improved by prolonged time to surgery in the no-boost group, a progressive and significant pCR improvement in patients treated with boost over time was observed. RT boost seems to be beneficial only in more advanced primary tumors.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Nicosia L, Bonù ML, Angelicone I, et al. Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study - ATLANTIS part I. Radiother Oncol. 2024. PMID: 40130646. doi:10.1016/j.radonc.2024.110701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。